Inventiva (IVA)
(Delayed Data from NSDQ)
$3.49 USD
-0.01 (-0.34%)
Updated Aug 7, 2025 10:09 AM ET
2-Buy of 5 2
F Value A Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IVA 3.49 -0.01(-0.34%)
Will IVA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IVA
Inventiva (IVA) Upgraded to Buy: What Does It Mean for the Stock?
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?
IVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for IVA
12 Health Care Stocks Moving In Friday's Intraday Session
Inventiva (IVA) Welcomes New Leadership in R&D and Medical Management | IVA Stock News
Inventiva CMO Michael Cooreman to depart, Jason Campagna to succeed
Inventiva receives $10M milestone payment from Chia Tai-Tianqing Pharmaceutical
12 Health Care Stocks Moving In Wednesday's After-Market Session